PMID- 21499281
OWN - NLM
STAT- MEDLINE
DCOM- 20111227
LR  - 20211020
IS  - 1745-7262 (Electronic)
IS  - 1008-682X (Print)
IS  - 1008-682X (Linking)
VI  - 13
IP  - 5
DP  - 2011 Sep
TI  - Comparison of the clinical efficacy of medical treatment of symptomatic benign 
      prostatic hyperplasia between normal and obese patients.
PG  - 728-31
LID - 10.1038/aja.2011.5 [doi]
AB  - We aimed to investigate the difference in efficacy of medical treatment of 
      symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients 
      with BPH; obesity was determined by either body mass index (BMI) or waist 
      circumference (WC). In this 12-week prospective observational study, a total of 
      175 patients aged >/=40 years with International Prostate Symptom Scores (IPSS) >/=12 
      points and prostate volume >/=20 ml were prospectively enrolled. The patients were 
      divided into two groups according to BMI or WC. Patients received the doxazosin 
      gastrointestinal therapeutic system (GITS) at a dose of 4 mg once per day for 12 
      weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q(max)), 
      post-void residual volume, quality of life (QoL) scores and adverse events (AEs) 
      were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven 
      patients had BMI >23 kg m(-)(2), and 43 had WC >90 cm. Obese patients represented by 
      WC >90 cm or BMI >/=23 kg m(-)(2) had a significantly greater prostate volume compared 
      with non-obese patients at baseline. Total IPSS was significantly higher in the 
      WC >90 cm group compared to the WC </=90 cm group. Total IPSS was positively 
      correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed 
      significant improvements in total IPSS and QoL at 12 weeks. However, the 
      improvement of total IPSS was greater in the high-BMI and high-WC groups. The 
      most frequent AE was dizziness (n=13), and it was significantly lower in the 
      obese BPH patients. Obesity was associated with increased prostate volume and 
      lower urinary tract symptoms. Alpha-blockers appear to be efficacious for 
      controlling symptoms, especially in obese men.
FAU - Lee, Seung Hwan
AU  - Lee SH
AD  - Department of Urology, Yonsei University Health System, Seoul, Korea.
FAU - Oh, Cheol Young
AU  - Oh CY
FAU - Park, Kyung Kgi
AU  - Park KK
FAU - Chung, Mun Su
AU  - Chung MS
FAU - Yoo, Se Jeong
AU  - Yoo SJ
FAU - Chung, Byung Ha
AU  - Chung BH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110418
PL  - China
TA  - Asian J Androl
JT  - Asian journal of andrology
JID - 100942132
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - NW1291F1W8 (Doxazosin)
SB  - IM
CIN - J Urol. 2012 Oct;188(4):1235. PMID: 22971392
MH  - Adrenergic alpha-1 Receptor Antagonists/administration & dosage/therapeutic use
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Doxazosin/administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Obesity/*physiopathology
MH  - Prospective Studies
MH  - Prostatic Hyperplasia/*drug therapy/physiopathology
PMC - PMC3739575
EDAT- 2011/04/19 06:00
MHDA- 2011/12/28 06:00
PMCR- 2011/09/01
CRDT- 2011/04/19 06:00
PHST- 2011/04/19 06:00 [entrez]
PHST- 2011/04/19 06:00 [pubmed]
PHST- 2011/12/28 06:00 [medline]
PHST- 2011/09/01 00:00 [pmc-release]
AID - aja20115 [pii]
AID - 10.1038/aja.2011.5 [doi]
PST - ppublish
SO  - Asian J Androl. 2011 Sep;13(5):728-31. doi: 10.1038/aja.2011.5. Epub 2011 Apr 18.